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Introduction: The impact of decision-making during the development and the regulatory
review of medicines greatly influences the delivery of new medicinal products. Currently,
there is no generic instrument that can be used to assess the quality of decision-making.
This study describes the development of the Quality of Decision-Making Orientation
Scheme QoDoS© instrument for appraising the quality of decision-making.
Methods: Semi-structured interviews about decision-making were carried out with 29
senior decision makers from the pharmaceutical industry (10), regulatory authorities (9)
and contract research organizations (10). The interviews offered a qualified understanding
of the subjective decision-making approach, influences, behaviors and other factors that
impact such processes for individuals and organizations involved in the delivery of new
medicines. Thematic analysis of the transcribed interviewswas carried out using NVivo8®
software. Content validity was carried out using qualitative and quantitative data by an
expert panel, which led to the developmental version of the QoDoS. Further psychometric
evaluations were performed, including factor analysis, item reduction, reliability testing
and construct validation.
Results: The thematic analysis of the interviews yielded a 94-item initial version of the
©QoDoS with a 5-point Likert scale. The instrument was tested for content validity using
a panel of experts for language clarity, completeness, relevance and scaling, resulting in
a favorable agreement by panel members with an intra-class correlation coefficient value
©of 0.89 (95% confidence interval = 0.56, 0.99). A 76-item QoDoS (version 2) emerged
from content validation. Factor analysis produced a 47-item measure with four domains.
©The 47-item QoDoS (version 3) showed high internal consistency (n = 120, Cronbach’s
alpha = 0.89), high reproducibility (n = 20, intra-class correlation = 0.77) and a mean
completion time of 10min. Reliability testing and construct validation was successfully
performed.
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Conclusion: The QoDoS© is both reliable and valid for use. It has the potential
for extensive use in medicines development by both the pharmaceutical industry and
regulatory authorities. The QoDoS© can be used to assess the quality of decision-making
and to inform decision makers of the factors that influence decision-making.
Keywords: QoDoS, decision-making tool, quality decision, regulatory decisions, submission decisions
INTRODUCTION
Decisions needed in the development of new medicines
commonly have to be made based on insufficient data, a high
degree of uncertainty and significant economical stakes and
often occur in an environment of time pressure, in which
several stakeholders are competing to be the first in the market
with their specific drug candidate (Pritchard et al., 2003;
Chung-Stein, 2011). Decision-making among the regulators of
medicines and the pharmaceutical industry is driven by various
factors. The regulators must adhere to a remit to positively
impact public health whilst remaining mindful of precedents
and adhering to laws, regulations, and policies (Eichler et al.,
2008; Breckenridge et al., 2011). The pharmaceutical industry,
on the other hand, is motivated by the need to predictably
and transparently develop medicines that will fulfill patients’
needs and regulatory requirements whilst delivering profit to
shareholders (Breckenridge and Woods, 2005). Additionally,
it is recognized that there is a subjective human component
within the decision-making process (Donelan et al., 2015). This
subjective decision-making style reflects the combination of how
an individual perceives and comprehends stimuli and the general
manner in which he or she chooses to respond to it. It is linked
to an individual’s knowledge, ability, motivation, their value
orientation and tolerance for ambiguity (Kahenman, 2011).
A review of the literature demonstrates that research and
insight into the decision-making approaches and considerations
by individuals and organizations involved in medicines research
and development is currently lacking. A novel qualitative study
investigated the factors influencing quality decision-making
(regulatory and pharmaceutical industry perspectives) (Donelan
et al., 2015). The outcomes of this qualitative research not only
identified the hallmarks of good decision-making practices that
could be adopted by all stakeholders at the individual and/or
organizational level, but it also emphasized the different focus
of the decision-making undertaken by the stakeholders and
provided the informed impetus for the development of the
generic tool (the QoDoS©). An enhanced appreciation may
facilitate a clearer understanding of decision-making approaches
and this in-turn could help to identify or enable improved
decision-making practices for both the individual and the
organization. It was this setting that stimulated the research
that ultimately led to the development and validation of a
generic decision-making instrument, the Quality of Decision
Abbreviations: CI, confidence interval; CRO, contract research organization; EU,
European Union; ICC, intra-class correlation coefficient; KMO, Kaiser-Meyer-
Olkin; MTMM, multi-trait multi-method; QoDoS, Quality of Decision-Making
Orientation Scheme.
Orientation Scheme (QoDoS), to assess the quality of decision
making.
METHODS
A mixed-methods research approach was adopted comprising
both qualitative and quantitative components and considered
appropriate for a study of this nature (Hanson et al., 2005).
An outline of the development stages of a decision-making
instrument is shown in Figure 1. The developmental version
of the instrument went through several stages of refinement
resulting in a 47-item final version of the QoDoS© (Figures 2, 3).
The main stages of the research were; item generation
from qualitative interviews, content validation, psychometric
evaluation, factor analysis, item reduction, reliability testing and
construct validation.
Item Generation
Ninety-four items were generated from the decision-making
themes and sub-themes that emerged from the qualitative
interviews with 29 senior decision makers regarded as key
opinion leaders from the pharmaceutical industry and regulatory
authorities to form the first version of the instrument (Donelan
et al., 2015). Each item measured one concept in a clear and
concise manner. Content validation and psychometric evaluation
testing were performed, resulting in a reduced list of items in
the form of the 76-item QoDoS© (version 2) questionnaire. This
then underwent further item reduction using factor analysis,
reliability testing and construct validation, resulting in the final
47-item QoDoS (version 3) instrument.
Participants: Qualitative Phase
Interviews Stage (Cohort 1)
Twenty-nine senior decision makers [9 Regulatory Agency; 10
Pharmaceutical Industry; 10 Clinical Research Organization’s
(CROs)] regarded as key opinion leaders from the European
Union (EU) and United States pharmaceutical industry, EU
regulatory authorities and contract research organizations
(CROs) were interviewed. The sample was chosen because
of their active engagement and recognized status in the
development, review and delivery of medicinal products.
Content Validation Stage (Cohort 2)
A six-member expert panel of experienced senior decision
makers from regulatory agencies and the pharmaceutical and
CRO industry carried out the content validation on the initial
94-item QoDoS©. The pharmaceutical industry (two) and CRO
(two) panel members were all experienced professionals at
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FIGURE 1 | Development of the QoDoS© decision-making instrument.
advanced managerial level and all with more than 7 years’
experience (range = 7–30 years). The regulatory agency experts
(two) were experienced “assessors” with more than 7 years’
regulatory agency experience. All content validation panel
members considered themselves experienced and experts in
decision making.
Each expert member of the content validation panel
participated in two ways: first, by individually completing the 94-
item developmental questionnaire and the rating of each item
using a 4-point Likert scale. Second, by participating in an all
panel roundtable discussion meeting once all six feedback forms
had been analyzed.
In the content validation, intra-class correlation coefficient
(ICC) and reliability (Cronbach’s alpha) measurements were
determined using SPSS20 statistical software (Pallant, 2005; IBM,
2015). The content validity index (CVI) and scale content validity
index (S-CVI) were also calculated for the expert panel review
results using Microsoft Excel R©. The CVI can be calculated on
an item level (I-CVI) and scale level (S-CVI). The item content
validity index (I-CVI) is calculated as a level of agreement
among a panel of judges for each individual item; that is, the
proportion of experts who rate it as content valid. The scale
content validity index (S-CVI) is defined as “the proportion of
total items judged content valid” (Lynn, 1986; Polit and Beck,
2006). The 76-item QoDoS© (Version 2) was the outcome of the
content validation.
Participants: Quantitative Phase
Factor Analysis and Item Reduction Stage (Cohort 3)
A sample of 120 individuals from the pharmaceutical industry
(n = 76), regulatory authorities (n = 21), CROs (n =
23) from EU, US, Middle East and Singapore participated in
the quantitative factor analysis and item reduction phase. This
sample was broad, representing the target population.
There were two distinct research component phases involved
in the factor analysis and item reduction stage. In component
phase 1, a study was conducted using the QoDoS R© (version 2)
in a large sample to investigate the decision-making approach
of individuals and their respective organizations. All participants
were asked to complete and return the electronic version
of the QoDoS© (version 2). In component phase 2, the
quantitative data generated in phase 1 was transposed into
statistical format ready for factor analysis and item reduction
(Cattell, 1978).
Construct Validation and Reliability Testing Stage
(Cohort 4)
The QoDoS© instrument that had undergone factor analysis
was evaluated for reliability and construct validity using 76
individuals from regulatory agencies and the pharmaceutical
healthcare arena. All participants were asked to respond to each
of the QoDoS© 47-items using a 5-point Likert scale: 0 = not at
all, 1= sometime, 2= frequently, 3= often 4= always.
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FIGURE 2 | Quality of Decision-Making Orientation Scheme (QoDoS)© . questionnaire: organizational-level influences.
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FIGURE 3 | Quality of Decision-Making Orientation Scheme (QoDoS)©. questionnaire: individual-level influences.
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The additional 76 individuals from the pharmaceutical
industry (46), regulatory authorities (18) and contract research
organizations (12) from Europe, US and China were recruited
for this stage. This was a diverse sample representing the target
population.
Statistical Analysis
Statistical analyses formed the basis of the construct validation
and assessed the correlations between the QoDoS© construct
domains. The reliability and construct validity were tested
using standard statistical techniques including the Principal
Component Analysis (PCA), Cronbach’s alpha for reliability
accompanied by ICC coefficient and Spearman’s 2-tailed
correlation statistic (Floyd and Widaman, 1995). Kaiser-Meyer-
Olkin (KMO) and Bartlett’s Sphericity testing and correlation
statistics were also performed. A multi-trait multi-method
(MTMM) table was generated capturing comparative statistical
methodologies.
Ethical Approval and Consent
Because of the nature of the research (interviews and surveys with
senior executives in pharmaceutical companies, contract research
organizations and regulatory agencies) Ethics Board approval
was not required. However, all study participants were provided
with an information sheet about the study and were informed of
all participant requirements.
All study participants provided informed verbal consent.
Data Availability
Because of the positions of study participants within their
organizations and the sensitive nature of the data that they
provided, confidentiality regarding that data was a specification
of the study.
All study participants received assurance of the confidential
nature of the study and were informed that individual responses
(study data) would not be divulged to anyone apart from the
research teamwho had entered into the confidentiality agreement
with the subjects and would only be reported in an aggregated
form.
RESULTS
Content Validity
The content validation of the 94-item developmental QoDoS©
(version 1) used both qualitative and quantitative methods with a
6-member expert panel of regulatory and industry professionals.
The questionnaire feedback forms (n = 6) from the
quantitative part of the content validity demonstrated good
agreement among the judges, intra-class correlation (ICC)= 0.89
(P < 0.0001; 95% confidence interval [CI] = 0.56, 0.99). Ninety-
five percent of judges thought that the items were complete,
written clearly, were relevant to decision makers and fitted well
with the response options. The scale content validity index (CVI)
for the 94-item developmental instrument was calculated as 0.85,
confirming content validity of the QoDoS©. The Cronbach’s
alpha reliability of the ratings of six expert panel members was
0.91, indicating a high level of internal consistency. The expert
panel review resulted in the reduction of the original 94 items to
76 items (version 2) and with editorial language changes being
made to some of the items. The QoDoS© (version 2) comprised
35 organizational- related decision-making items and 41 related
to the “individual.” Content validity was successfully evaluated
and the QoDoS© (version 2) deemed fit for purpose and suitable
for further item reduction.
Item Reduction
Item reduction was carried out using factor analysis through
which relevant factors were identified.
Factor Analysis
In this study, there were two distinct but linked stages in the
factor analysis performed on the 76-item QoDoS© (version 2).
The first stage recruited 600 people into the study. A total of
130 took part and completed the QoDoS© (version 2), of which
120 were evaluable. This sample was representative of the target
population. The proprietary Survey Monkey web-based platform
package was used in this study.
In addition to the factor analysis and item reduction, the
research results obtained from the 120 evaluable participants
provided insights into decision making from the perspective of
the individual and also that of the organization in which they
were/are employed. The research also allowed for comparisons to
be made across the three main organizations that participated in
the study; that is, regulatory agencies, pharmaceutical companies
and CROs.
Organizational-Related Items
A 12-step factor analysis was performed on the 35 organizational
related domains of the QoDoS© (version 2) using SPSS 20. This
helped to explore the underlying structure of the 35 items, to
confirm appropriateness and to further develop the instrument
by reducing inappropriate items that did not contribute to
underlying domain factors of the instrument. Reliability testing
using Cronbach’s alpha and ICC were measured along with
KMO and Bartlett’s testing. Scree plots were generated at each
factor analysis stage. The reliability statistics performed resulted
in a Cronbach’s alpha of 0.78 for the initial 35 Organizational
items. The average ICC value for the initial organizational items
was 0.77.
Exploratory factor analysis of the 35 organizational items was
used to reduce the number of items if necessary (Figure 4). Items
that failed to load on any component or had a weak loading
of <1 were removed, reducing the overall organizational-related
decision-making items to a final list of 23 items. The component
matrix for the extracted variables was rotated using Varimax
functionality (Pallant, 2005). This Varimax rotation helped to
confirm the initial structure of the scale and delivered a matrix of
the factor loadings for each variable onto each of the two evident
factors. Loading values with a unique value of less than 0.4 were
suppressed.
Individual Related Items
A total of 11 consecutive factor analysis item reduction steps
were performed on the 41 “individual related items” of QoDoS R©
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FIGURE 4 | Scree plot of 35-item organizational-related items.
(version 2). Reliability testing using Cronbach’s alpha and ICC
weremeasured along with KMO, scree plots and Bartlett’s testing.
The reliability statistics performed resulted in a Cronbach’s alpha
of 0.81 for the initial 41 Individual related items. The average ICC
value for the initial individual items was 0.80.
Exploratory factor analysis of the 41 individual items was
again used to reduce the number of items if necessary, using the
same criteria as applied to the organizational items. Items that
failed to load on any component or had a weak loading of <1
were removed, reducing the overall individual related decision-
making items to a final list of 22 items. The component matrix for
the extracted variables was rotated using Varimax functionality.
This Varimax rotation helped to confirm the initial structure of
the scale and delivered a matrix of the factor loadings for each
variable onto each of the two evident factors. Loading values with
a unique value of less than 0.4 were suppressed.
Following the factor analysis process, the initial emergent
source themes on organizational (21) and individual (22) related
decision-making behavior were reviewed in order to resolve
the tension between the qualitative content analysis and the
outcomes of the application of statistical modeling. It was decided
to retain some of the removed items which were very highly
prevalent in the qualitative study. The proposed additional
items were based on the research teams’ personal and expert
professional perspective and also with cognizance of the output
from the key opinion leaders’ interviews. The resultant outcome
of the final factor analysis and the thorough review of the
qualitative results was the delivery of the 47-item QoDoS©
(version 3) instrument. The instrument comprised two domains;
Part 1 for organizational-level decision-making, consisting of
23 items (Figure 2) and Part 2: for individual-level approaches
consisting of 24 items (Figure 3). Subsequently, each component
was grouped into two separate construct domain categories. Two
behavioral domain constructs were identified for the organization
(Approach and Culture) and two relating to the individual
(Competence and Style).
Reliability and Construct Validation
Reliability and construct validity testing was performed on the
QoDoS© and its four component constructs using statistical
methodologies complemented by additional semi-quantitative
techniques (Westen and Rosenthal, 2003; Trochim, 2015). For
each of the four construct categories, reliability was tested
using Cronbach’s alpha and ICC. For all four categories, the
reliability coefficient was shown to be greater than Cronbach’s
alpha and ICC of 0.73. The consistency and reproducibility of
the reliability findings across time as well as the different items
and measurement methodologies supported the assertion that
appropriate reliability was observed. The reliability, the internal
consistency and the ICC of the measures observed were also
indicative of the homogeneity of the component items that
tapped into each of the two organizational constructs (Approach
and Culture) and those for the individual (Competence and Style).
A secondary outcome of this study has been the rich insights
and understanding into the decision-making practices of the 120
individuals and the organizations who participated in the factor
analysis part of the study. A wealth of information was generated
and this allowed several comparative reviews of perspective from
that of the individual and the organization. This provided insight
into the variance in distribution of results obtained from the
three organizations. The initial comparative statistical analyses
performed on the items of the organizational component of the
QoDoS© showed a high level of correlation among the regulatory
authorities, pharmaceutical companies and CROs.
From the perspectives of the individual, the results showed
that participants felt that they could make better decisions and
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that an investment in training and education would benefit
them and their decision-making. There was a lack or routine
usage of decision-making tools such as strengths, weaknesses,
opportunities threats (SWOT) analysis and limited experience
of modeling and simulation. Other perspectives that emerged
were that individuals felt that they were more accountable for
their decisions than the organization was at the organizational
level and that professional experience was a key component
that influenced decision-making. The results also showed the
importance of clearly understanding the context of the decision.
In total, the individual’s perspective was obtained in response
to 24 specific questions on their decision-making style and
competence and factors that impact them.
Similarly, insights were gained from the 120 study participants
on the decision-making perspective of their organization through
their responses to 23 items of Part I of the QoDoS©. The results
showed the factors influencing organizations’ decision-making.
These included: the culture of the organization; the lack of
training in decision making provided within the organization;
the internal and external competitor influences; performance
of an impact analysis of decisions made; re-evaluation of a
decision on the basis of new data becoming available; and
transparency within the decision-making process. A variance in
the distribution of the response profiles to the individual- and
organizational-focused questions was evident across the three
organizations involved in the research.
DISCUSSION
The development and initial psychometric properties of a
new instrument designed to assess the quality of decision-
making have been described. QoDoS© is the first instrument
specifically developed to assess the quality of decision making
in medicines’ development and review using a standardized
rigorous methodology. The foundation for the QoDoS©
development was the earlier novel qualitative study performed
which investigated the factors influencing quality decision-
making (regulatory and pharmaceutical industry perspectives).
(Donelan et al., 2015) The outcomes of this research identified
the hallmarks of good decision-making practices that could
be adopted by all stakeholders at the individual and /or
organizational level, but also led to the development of the
generic tool intended for use by all stakeholders. TheQoDoS© is a
generic instrument designed to be used across all pharmaceutical
research and development disciplines and regulatory agencies.
An adequate number of subjects took part in the qualitative
interview stage (n = 29) as well as in the subsequent
development (120) and psychometric evaluation (n = 76)
stages of the instrument including factor analyses, reliability and
construct validation testing. The final version of the QoDoS© is
easy to understand straightforward and can be completed within
10min.
At the initial development stage a robust number of emergent
decision-making themes (n = 94) generated from interviews
with industry and regulatory agency key opinion leaders were
incorporated into the questionnaire development to ensure
that no aspect of decision making was overlooked from the
perspective of the organization or the individual. Content
validation helps to examine whether a proposed measurement
tool possesses the right emphasis and focus for the concept being
measured and the target population. In the content validation
of the 94-item instrument, both qualitative and quantitative
assessment techniques were applied to ensure that the QoDoS©
scale had enough items and adequately covered each of the
domains being measured. This is a primary validation step which
helps to complement, endorse and increase the probability of
obtaining high construct validation in the development of an
instrument (Denzin and Lincoln, 2005). In this study, the expert
panel involved in the content validation discussed and gave
opinions on each questionnaire item, which led to a refined valid
instrument.
We applied factor analysis, which is a well-established
statistical technique for item reduction in instrument
development. The strength of factor analysis lies with its
ability to identify the relationships between a set of variables
(items) measured or observed, in particular for those with similar
(Bhatti et al., 2013) or overlapping constructs. In this study, factor
analysis was used to confirm the grouping of the instrument
items, which had been based on subjective opinion, through the
use of mathematical modeling. It allowed the reduction of a large
number of correlated variables to a more manageable number
and resulting in a final quantity of 47 items in the instrument,
which rendered it a more user-friendly tool. The outcome of
the factor analysis was the delivery of the final version of the
QoDoS© instrument (version 3), capturing organizational and
individual decision-making items representing the approach,
culture, competence and decision-making style.
Factor analysis was followed by a demonstration of
appropriate evidence of construct validity, examining
convergence (evidence that different measurement methods
of a construct give similar results) and discriminability (ability to
differentiate the construct from other related constructs) of the
QoDoS© constructs. This analysis showed that the instrument
possesses strong measurement properties of reliability and
validity.
The secondary outcome study results have provided
additional insights regarding the differing dimensions of the
decision-making perspectives of organizations compared with
those of individuals. For organizations, the modus operandi,
the working environment and the shared beliefs and values
of the organization appeared to be important influences. For
individuals, the subjective elements of professional experience,
ability, empowerment or autonomy and preference appeared to
be factors influencing decision-making.
Potential Limitations
Potentially, studies of this nature have certain limitations. The
participants in the qualitative phase of the research were all
senior decisionmakers whowere regarded as key opinion leaders.
Whilst this cohort provided rich insights into their decision-
making approaches and styles, these may not have been truly
representative of personnel involved in medicines’ development
and review. However, if less experienced people had participated
Frontiers in Pharmacology | www.frontiersin.org 8 July 2016 | Volume 7 | Article 180
Donelan et al. Quality Decision-Making Assessment Instrument
in the research, some decision-making themes that emerged
in this research may not have been uncovered. Additionally,
whereas the sample size achieved in the qualitative phase of the
research was satisfactory, this was not the case in the quantitative
phase, when only a 20% response rate was achieved despite the
use of recognized techniques of follow-up including repeat emails
and phone calls (Diem, 2002; Boynton, 2004; SurveyMonkey,
2015). The ideal number of participants in the final sample
would have been between 350 and 760; however, this would
have involved recruiting up to 3500 people, which was not an
achievable target. Moreover, whilst the QoDoS© research was
international in nature and did include participants from several
EU countries, United States, Middle East, Singapore and China,
it did not include South America or Japan, and decision making
in these regions may differ because of experience and culture.
Finally, the lack of a validated “gold-standard” instrument could
be perceived as a limitation as it precluded the opportunity for a
head-to-head comparison, which in turn would have reduced the
sample size requirement and also would have provided a different
construct validation approach.
CONCLUSIONS
QoDoS© offers an addition to the decision-making
armamentarium that provides a method to assess the quality
of decision making from the perspective of the individual and
the organization involved in the research, development and
delivery of new medicines. It can be used to inform decision
makers of factors impacting quality decision-making and be
incorporated into decision-making frameworks, presenting a
potential platform to add consistency, transparency and ease of
communication to the subjective decision-making element. It
can inform decision makers of factors impacting the methods
and components of the decision making processes used by the
pharma and CRO industries, as well as by regulatory authorities.
As the first generic quality of decision-makingmeasure, QoDoS©
has the potential to be used in a variety of health research areas
and beyond.
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